The Palo Alto startup has developed an AI-based system that can screen the retinal images of newborn babies to highlight potential eye conditions that require follow-up and treatment.
The company's technology for screening diabetic retinopathy was granted "Breakthrough Device" designation and is able to provide a clinical decision, instead of simply a recommendation to the physician.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The marketing clearance follows the FDA's decision to approve a "breakthrough device" designation for IDx-DR, accelerating the review process for the product based on its ability to address an unmet medical need.
Artificial intelligence is a white-hot buzzword. But amidst the hullabaloo, what can it actually achieve in the world of healthcare? Before weighing in on the topic at MedCity INVEST in May, experts from IDx, Arterys and AiCure share their thoughts.